• LAST PRICE
    2.1800
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-0.9091%)
  • Bid / Lots
    2.1700/ 4
  • Ask / Lots
    2.1800/ 2
  • Open / Previous Close
    2.2300 / 2.2000
  • Day Range
    Low 2.1400
    High 2.2399
  • 52 Week Range
    Low 2.0200
    High 18.0000
  • Volume
    85,747
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.2
TimeVolumePCSA
09:32 ET6272.2004
09:39 ET131642.22
09:50 ET25002.2399
10:02 ET59082.2
10:04 ET177732.18
10:09 ET46672.19
10:11 ET1002.17
10:15 ET15002.195
10:22 ET60712.195
10:27 ET13202.16
10:36 ET11002.19
10:42 ET15002.175
10:44 ET10002.18
11:02 ET2002.19
11:09 ET7242.17
11:12 ET1002.17
11:16 ET1002.17
11:25 ET55742.15
11:27 ET3002.16
11:36 ET2002.14
11:39 ET1002.16
11:41 ET1002.16
11:43 ET7002.16
11:50 ET73022.18
11:52 ET2002.18
11:54 ET1002.17
11:57 ET1002.17
11:59 ET1002.17
12:12 ET1002.18
12:19 ET1002.1769
12:28 ET1002.17
12:30 ET2992.17
12:42 ET20462.18
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPCSA
Processa Pharmaceuticals Inc
4.8M
-0.1x
---
United StatesKPRX
Kiora Pharmaceuticals Inc
4.5M
-0.1x
---
United StatesGRPS
Gold River Productions Inc
4.1M
0.0x
---
United StatesHOTH
Hoth Therapeutics Inc
5.6M
-0.3x
---
United StatesPRFX
PainReform Ltd
3.9M
-0.3x
---
United StatesSHPH
Shuttle Pharmaceuticals Holdings Inc
5.8M
-0.9x
---
As of 2024-02-26

Company Information

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing the Processa Regulatory Science Approach, including the principles associated with food and drug administration (FDA’s) project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of next generation chemotherapy (NGC) oncology drug products. Its pipeline consists of three oncology drugs (NGC-Capecitabine, NGC-Gemcitabine and NGC-Irinotecan) and two non-oncology drugs (PCS12852 and PCS499). NGC-Capecitabine is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD). NGC-Gemcitabine is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine resulting in a positive response in gemcitabine patients as well as some gemcitabine treatment-resistant patients. NGC-Irinotecan is a prodrug of the active metabolite of irinotecan (SN-38).

Contact Information

Headquarters
7380 Coca Cola Dr Ste 106HANOVER, MD, United States 21076-1789
Phone
443-776-3133
Fax
443-288-4420

Executives

Independent Chairman of the Board
Justin Yorke
Chief Executive Officer, Director
George Ng
Founder, Chief Administrative Officer
Wendy Guy
Chief Development Officer, Founder
Sian Bigora
Chief Financial Officer
James Stanker

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.8M
Revenue (TTM)
$0.00
Shares Outstanding
2.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.49
EPS
$-22.82
Book Value
$9.32
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.